canSAR.ai is an innovative cancer drug discovery platform, developed through a collaborative effort that includes the University of Texas MD Anderson Cancer Center and the Institute of Cancer Research in London. This public resource serves to advance cancer drug discovery and translational research globally by providing an integrated knowledgebase. It brings together diverse data from various fields including biology, pharmacology, and structural biology, applying cutting-edge machine learning and artificial intelligence techniques to offer meaningful predictions for drug development.

canSAR.ai serves as a comprehensive information portal where researchers can explore complex questions related to proteins, drug interactions, and cancer specificity. Whether it's understanding protein expressions in different cancers or assessing drug sensitivity profiles, canSAR.ai is dedicated to supporting multidisciplinary research efforts. This platform is freely accessible to the research community, inviting feedback and collaboration to continuously enhance its utility. With generous funding from organizations like Cancer Research UK and the Wellcome Trust, canSAR.ai remains at the forefront of cancer research innovation.